Provided by Tiger Trade Technology Pte. Ltd.

VanEck Pharmaceutical ETF

108.06
-0.0800-0.07%
Post-market: 108.060.00000.00%19:30 EDT
Volume:272.52K
Turnover:29.38M
Market Cap:1.01B
PE:87.56
High:108.33
Open:108.14
Low:107.29
Close:108.14
52wk High:118.00
52wk Low:90.60
Shares:9.39M
Float Shares:9.39M
Volume Ratio:0.61
T/O Rate:2.90%
Dividend:2.18
Dividend Rate:2.02%
EPS(TTM):1.23
EPS(LYR):0.7765
ROE:--
ROA:--
PB:--
PE(LYR):139.17

Loading ...

Eli Lilly - Foundayo Associated with Reduced Predicted Long-Term Risk of Type 2 Diabetes and Cardiovascular Disease

THOMSON REUTERS
·
Oct 01

Merck Schedules Third-Quarter Sales and Earnings Conference Call with Investors and Analysts

Reuters
·
Oct 01

Merck & Co Inc : Jefferies Raises Target Price to $177 from $175

THOMSON REUTERS
·
Oct 01

RBC Capital Keeps Their Hold Rating on Merck & Company (MRK)

TIPRANKS
·
Oct 01

The Next Frontier for Obesity Drugs Isn't How Much Weight You Lose, but What Kind

Dow Jones
·
Oct 01

Eli Lilly Says Foundayo Drug Helped Patients Lose Weight in Phase 3 Trial

Dow Jones
·
Oct 01

Eli Lilly’s Foundayo shows cardiovascular safety in type 2 diabetes study

TIPRANKS
·
Oct 01

Lilly's Oral Glp-1, Foundayo (Orforglipron), Demonstrated Cardiovascular Safety Alongside Sustained A1c Reduction and Weight Loss in Its Largest and Longest Type 2 Diabetes Study

THOMSON REUTERS
·
Oct 01

Eli Lilly - Achieve-4: Foundayo Shows 16% Lower Mace-4 and 23% Lower Mace-3 Risk vs Insulin Glargine

THOMSON REUTERS
·
Oct 01

Eli Lilly - Foundayo Shows Smaller Egrf Reduction and Greater Albuminuria Reduction vs Insulin Glargine

THOMSON REUTERS
·
Oct 01

Moderately bullish activity in Novo Nordisk with shares down 1.06%

TIPRANKS
·
Oct 01

Abbott Laboratories Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Oct 01

Merck, 3M Share Losses Contribute to Dow's 286-Point Drop

Dow Jones
·
Oct 01

Dow Drops 150 Points on Losses for Shares of Sherwin-Williams Co., Merck

Dow Jones
·
Oct 01

Sector Update: Healthcare

MT Newswires Live
·
Oct 01

Novo Nordisk Opens a New Front in Cardiometabolic Care With Early-Stage Anti-Inflammatory Study

TIPRANKS
·
Oct 01

Novo Nordisk Tests Cagrisema Switch Strategy to Strengthen Its Diabetes Franchise

TIPRANKS
·
Oct 01

Lilly’s Clazakizumab Trial Pushes Cardiovascular Inflammation Strategy Forward

TIPRANKS
·
Oct 01

AbbVie Wraps Key Early Trial on ABBV-722 Drug Interaction, Supporting Pipeline Confidence

TIPRANKS
·
Oct 01

AbbVie’s Bretisilocin Study Completion Signals Quiet Progress in Early-Stage Pipeline

TIPRANKS
·
Oct 01